Table 3.
Factor | Univariable HR (95% C.I) | p | Multivariable HR (95% C.I) | p |
---|---|---|---|---|
Blood NLR (< 4) | 0.63 (0.47–0.84) | 0.01 | 0.66 (0.45–0.96) | 0.03 |
Pleural fluid lymphocyte predominance | 0.52 (0.33–0.82) | 0.01 | 0.53 (0.32–0.89) | 0.02 |
Lymphocytic stroma predominance | 0.74 (0.59–0.93) | 0.01 | 0.55 (0.35–0.87) | 0.01 |
Age (per year) | 1.02 (1.01–1.04) | 0.01 | 0.98 (0.95–1.01) | 0.15 |
Male gender | 0.85 (0.56–1.29) | 0.45 | 0.66 (0.40–1.10) | 0.11 |
WHO PS (3–4) | 1.37 (1.12–1.67) | 0.01 | 2.60 (1.72–3.92) | 0.01 |
Epithelioid sub type | 0.61 (0.44–0.846) | 0.01 | 0.60 (0.39–0.93) | 0.02 |
Radiological Stage (1 & 2 vs 3 & 4) | 0.95 (0.53–1.69) | 0.08 | 0.74 (0.32–1.69) | 0.47 |
Received chemotherapy | 0.52(0.40–0.70) | 0.01 | 0.58 (0.40–0.84) | 0.04 |
NLR neutrophil/lymphocyte ratio, p < 0.05 defined as significant